You are here
Biologics are not only expensive, their costs have continued to rise. This is not only true for rheumatology, as other specialties have unique biopharmaceuticals that have changed prescribing paradigms.
Jim Davis of AdverseEvents.com write this article examining the costs of multiple sclerosis drugs based on a study published in the April 24, 2015, issue of Neurology. Despite the higher introductory prices of new agents, pricing of older agents have significantly risen, often exceeding the inflation rate. This is an insightful analysis of the problems associted with drug pricing in neurology - not that different from what we are seeing in rheumatology.